[go: up one dir, main page]

ATE465753T1 - Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden - Google Patents

Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden

Info

Publication number
ATE465753T1
ATE465753T1 AT03776419T AT03776419T ATE465753T1 AT E465753 T1 ATE465753 T1 AT E465753T1 AT 03776419 T AT03776419 T AT 03776419T AT 03776419 T AT03776419 T AT 03776419T AT E465753 T1 ATE465753 T1 AT E465753T1
Authority
AT
Austria
Prior art keywords
methods
compositions
diseases caused
treating diseases
papilloma virus
Prior art date
Application number
AT03776419T
Other languages
English (en)
Inventor
Kathleen Beach
Mary Hedley
Robert Urban
Roman M Chicz
Original Assignee
Eisai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Inc filed Critical Eisai Inc
Application granted granted Critical
Publication of ATE465753T1 publication Critical patent/ATE465753T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT03776419T 2002-10-21 2003-10-16 Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden ATE465753T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42006802P 2002-10-21 2002-10-21
US47148103P 2003-05-15 2003-05-15
PCT/US2003/032705 WO2004037175A2 (en) 2002-10-21 2003-10-16 Compositions and methods for treating human papillomavirus-mediated disease

Publications (1)

Publication Number Publication Date
ATE465753T1 true ATE465753T1 (de) 2010-05-15

Family

ID=32179780

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03776419T ATE465753T1 (de) 2002-10-21 2003-10-16 Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden

Country Status (8)

Country Link
US (2) US20060247190A1 (de)
EP (1) EP1556513B1 (de)
JP (2) JP2006503914A (de)
AT (1) ATE465753T1 (de)
AU (2) AU2003284239B2 (de)
CA (1) CA2502696A1 (de)
DE (1) DE60332377D1 (de)
WO (1) WO2004037175A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101180885B1 (ko) 2006-04-19 2012-09-10 포항공과대학교 산학협력단 자궁경부암의 예방 및 치료를 위한 사람 파필로마바이러스폴리펩타이드와 면역 증강제를 포함하는 조성물
CN101426810A (zh) * 2006-04-21 2009-05-06 特朗斯吉恩股份有限公司 基于hpv-18的乳头瘤病毒疫苗
JP2009534332A (ja) * 2006-04-21 2009-09-24 トランジェーヌ、ソシエテ、アノニム パピローマウイルスワクチン
CA3057039C (en) 2006-07-28 2023-02-28 The Trustees Of The University Of Pennsylvania Hiv consensus envelope sequences and methods for using same
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
CA2721366C (en) 2008-04-17 2017-06-06 Elizabeth Ann Vasievich Stimulation of an immune response by enantiomers of cationic lipids
CA2731444A1 (en) * 2008-09-02 2010-03-11 Antigen Express, Inc. Human papillomavirus / li-key hybrids and methods of use
EP2601968A1 (de) 2011-12-06 2013-06-12 Deutsches Krebsforschungszentrum HPV-abgeleitete Polynucleinsäure zur Therapie
ES2777935T3 (es) 2012-06-15 2020-08-06 Pds Biotechnology Corp Composiciones de vacunas de lípidos catiónicos y procedimiento de uso
CA2885741C (en) 2012-09-21 2023-10-17 Frank Bedu-Addo Vaccine comprising r-dotap
WO2017083820A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
BE1024774B1 (fr) * 2016-09-29 2018-07-02 Glaxosmithkline Biologicals Sa Compositions et procedes de traitement
JP2020515542A (ja) * 2017-03-23 2020-05-28 ザ ジェネラル ホスピタル コーポレイション Ｃｘｃｒ４／ｃｘｃｒ７の遮断およびヒトパピローマウイルス関連疾患の治療
US20230241207A1 (en) * 2017-04-03 2023-08-03 Neon Therapeutics, Inc. Protein antigens and uses thereof
WO2021026335A1 (en) * 2019-08-08 2021-02-11 The Trustees Of Indiana University Methods for identifying and treating urinary tract infections
CN112957461B (zh) * 2021-02-02 2023-01-10 南开大学 一种形貌可控自佐剂宫颈癌多肽疫苗的制备及性能表征方法
WO2024180232A1 (en) * 2023-03-02 2024-09-06 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Therapeutic hpv vaccines based on validated target epitopes

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930007580B1 (ko) * 1986-03-21 1993-08-13 엥스띠뛰 빠스뙤르 유두종 비루스 게놈으로부터 유도된 결정 dna 서열, 그의 시험관내 진단 목적용 용도 및 항원 조성물의 제조 방법
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
US6007806A (en) * 1986-08-13 1999-12-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
DE3907721A1 (de) * 1989-03-10 1990-09-20 Behringwerke Ag Immunogene regionen auf dem e7-protein des humanen papillomvierus typ 16
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5753233A (en) * 1990-05-10 1998-05-19 Behring Diagnostics Gmbh Seroreactive epitopes on proteins of human papilloma-virus (HPV) 18
US5932412A (en) * 1990-05-11 1999-08-03 Euro-Diagnostica Ab Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US6183745B1 (en) * 1990-12-12 2001-02-06 The University Of Queensland Subunit papilloma virus vaccine and peptides for use therein
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US5543294A (en) 1991-07-19 1996-08-06 The Trustees Of Columbia University In The City Of New York Polymerase chain reaction/restriction fragment length polymorphism method for the detection and typing of myobacteria
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
EP0630234B1 (de) * 1992-03-12 1997-06-11 Alkermes Controlled Therapeutics, Inc. Acth enthaltende mikrokugeln mit gesteuerter abgabe
CA2142007C (en) * 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
US5462520A (en) 1992-08-17 1995-10-31 Genetronics, Inc. Transsurface drug delivery by electrofusion of microbubbles to the tissue surface
US5633234A (en) * 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
JPH08508252A (ja) * 1993-03-17 1996-09-03 アメリカ合衆国 小胞体シグナル配列ペプチドと少なくとも１個の他のペプチドをエンコードする核酸配列を含有する免疫原性キメラ、及びこのキメラのワクチン及び疾患の治療における使用
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5679509A (en) * 1993-09-28 1997-10-21 University Of New Mexico Methods and a diagnostic aid for distinguishing a subset of HPV that is associated with an increased risk of developing cervical dysplasia and cervical cancer
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
WO1995024929A2 (en) 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
WO1996025507A2 (en) 1995-02-17 1996-08-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of preparation and use of recombinant adenoviral vectors
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5705151A (en) * 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
US5626161A (en) * 1996-04-29 1997-05-06 Fu Tai Umbrella Works, Ltd. Multiple-fold automatic umbrella with simplified reliable control means
EP0934083B1 (de) * 1996-10-23 2009-04-29 The Trustees Of The University Of Pennsylvania Verbesserte impfstoffe
US20020103145A1 (en) * 1999-05-19 2002-08-01 Adrian Bot Immunization of infants
EP0957936B1 (de) * 1996-12-20 2006-10-04 MERCK & CO., INC. Zusammensetzungen von rekombinanten papillomavirus vakzinen
US5783567A (en) 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US6183746B1 (en) * 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
GB9722766D0 (en) 1997-10-28 1997-12-24 British Telecomm Portable computers
JP2001526045A (ja) 1997-12-12 2001-12-18 ダイジーン・コーポレーション ヒトパピローマウイルス関連疾患の評価
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
EP1078092B1 (de) * 1998-05-13 2011-08-03 Epimmune Inc. Expressionsvektoren zur stimulierung einer immunantwort und verfahren zu deren verwendung
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
AU771262B2 (en) 1998-08-12 2004-03-18 Eisai Inc. Profiling and cataloging expressed protein tags
EP1108035B1 (de) * 1998-09-04 2007-08-08 Sanofi Pasteur Limited Behandlung von gebärmutterhalskrebs
CA2276066A1 (en) 1999-03-11 2000-09-11 Zycos Inc. Microparticles for delivery of nucleic acid
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
EP1214097B3 (de) * 1999-09-16 2011-07-20 Eisai Inc. Für polyepitop-polypeptide kodierende nukleinsäuren
WO2001027291A1 (en) * 1999-10-12 2001-04-19 Institut Pasteur Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
ATE319810T1 (de) 1999-11-19 2006-03-15 Zycos Inc Durchflussverfahren zur herstellung von mikropartikeln
WO2001097795A2 (en) 2000-06-22 2001-12-27 3M Innovative Properties Company Systems and methods for treating a mucosal surface
MXPA02012858A (es) * 2000-06-26 2004-04-20 Stressgen Biotechnologies Corp Tratamiento de virus de papiloma humano.
GB0017990D0 (en) * 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences

Also Published As

Publication number Publication date
DE60332377D1 (de) 2010-06-10
US20060247190A1 (en) 2006-11-02
EP1556513A2 (de) 2005-07-27
AU2003284239A1 (en) 2004-05-13
AU2008249148A1 (en) 2008-12-11
AU2003284239B2 (en) 2008-08-21
WO2004037175A2 (en) 2004-05-06
CA2502696A1 (en) 2004-05-06
EP1556513B1 (de) 2010-04-28
EP1556513A4 (de) 2007-03-14
US20110158952A1 (en) 2011-06-30
JP2011121946A (ja) 2011-06-23
JP2006503914A (ja) 2006-02-02
WO2004037175A3 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
ATE465753T1 (de) Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
Coccia et al. Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity
WO2005089164A3 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
ATE314095T1 (de) Virusähnliche partikel zur induktion von autoantikörpern
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
EP4248983A3 (de) Antigenspezifische immuntherapie für covid-19-fusionsproteine und verwendungsverfahren
EA200601671A1 (ru) Идентификация собственных и чужеродных антигенов, вовлечённых в аутоиммунные заболевания
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
EA200401405A1 (ru) Модифицированный осповакцинный вирус анкара для вакцинации новорожденных
WO2008034388A8 (fr) Particules virales de protéines de la capside provenant du papillomavirus humain de type 16/58/18/6/11 et leur procédé de préparation et leurs utilisations
El Garch et al. An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses
MX2022012647A (es) Composiciones que comprenden tres proteinas de fusion de ospa para uso medico.
JP2010506926A5 (de)
EP1471936A4 (de) Hiv-vakzine und anwendungsverfahren
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
Shi et al. Expressions of Bovine IFN-γ and Foot-and-Mouth Disease VP1 antigen in P. pastoris and their effects on mouse immune response to FMD antigens
Haruna et al. Local production of broadly cross‐reactive IgE against multiple fungal cell wall polysaccharides in patients with allergic fungal rhinosinusitis.
TW200509964A (en) VP1 of foot-and-mouth disease virus
Farnós et al. The recombinant rabbit hemorrhagic disease virus VP60 protein obtained from Pichia pastoris induces a strong humoral and cell-mediated immune response following intranasal immunization in mice
CN1244804A (zh) 肽基免疫治疗剂
EP4295861A1 (de) Neue behandlung und prävention auf basis eines neuen verfahrens zur kontrolle der zellulären immunität
WO2004031354A3 (en) Human sarcoma-associated antigens
Munir et al. Crimean-Congo hemorrhagic fever: Immunopathogenesis and recent advances in the development of vaccines
JP2018538280A5 (de)
Riedmann Human vaccines and immunotherapeutics: news

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties